In IBD patients receiving intravenous infliximab, combination therapy with immunomodulators is associated with higher drug levels, less immunogenicity and subsequent greater disease control compared with those treated with anti-TNF monotherapy [66,78,79,80,81,82]. The gene discussed is TNF; the disease is inflammatory bowel disease.